A team of EPFL scientists has developed several antibody-based biosensors that have the potential to help healthcare centers in developing countries or even patients in their own homes keep track of drug concentration in the blood.
Being able to monitor drug concentration in the blood of a patient is an important aspect of any pharmaceutical treatment. However, this requires equipment and facilities that are often missing from field healthcare in developing countries, but also inhibits the quality of life for patients elsewhere. EPFL scientists, working through their startup LUCENTIX, have now developed an antibody-linked biosensor that can track drug concentration in the blood by changing its color. The biosensor is incorporated into a full system that can be used in the field or by patients at home. The science behind it is published in Angewandte Chemie.
The lab of Kai Johnsson at EPFL is known for developing biosensors, and the research gave birth to the startup LUCENTIX, which has developed a biosensor that allows patients to easily measure drug concentrations in their system without need for complex lab systems.
The biosensor is a molecule made up of three components: First, a protein that can bind the drug to be monitored. Second, the light-producing enzyme luciferase. And third, a “tagging” molecule called SNAP-tag, which carries a fluorescent ligand that the protein (the first component) recognizes and binds when no drug is present. This causes a reaction between the luciferase and the fluorescent molecule called “bioluminescent resonance energy transfer” (BRET), which produces a red light.
The recent innovation, carried out by postdoc Lin Xue, involves replacing the binding protein of the biosensor with part of an antibody that has been developed against the target drug. When the biosensor detects and binds the drug in the patient’s blood or saliva, the antibody “prefers” to bind this rather than the SNAP-tag’s fluorescent ligand. As the ligand is displaced, the BRET reaction is progressively disrupted, and now emits a blue light.
Antibodies are naturally able to identify and bind foreign molecules, turning our immune systems against potential infections. In addition, generating antibodies that can specifically identify small molecules like drugs is a routine procedure. This means that the monitoring system can be adapted to virtually an unlimited number of molecules, while patients can carry out the monitoring themselves at home and receive laboratory-level quality information. Current lab methods for doing this are complex and expensive, and reduce the quality of life for patients who have to often be confined within or close to hospitals.
Replacing the binding protein with an antibody establishes a general pipeline for the generation of biosensors that can identify a synthetic drug in a patient’s blood sample. As proof-of-principle, the EPFL scientists successfully tested the new biosensors against three drugs – methotrexate, theophylline, and quinine – in the lab. The next step will be to optimize the biosensor’s sensitivity so that it can accurately detect the nanomolar or even lower concentrations of drugs/biomolecules in clinical samples.
The Latest on: Point-of-care drug monitoring
- Point of Care Testing Market Size Worth USD 38.40billion by 2026: Acumen Research And Consulting on February 18, 2019 at 8:00 am
On the basis of product, the global point of care testing market is segmented into Glucose monitoring (Strips ... Hematology testing products, Drug-of-Abuse (DoA) testing products, Fecal occult testin... […]
- How to Buy Clinical Chemistry Analyzers on February 14, 2019 at 4:37 am
Learn about the different types of technology, laboratory integration, point-of-care analyzers and other important considerations ... Clinical applications of these analyzers include the monitoring of ... […]
- At 7.2% CAGR, Point of Care Testing Market Size Set to Register 34.2 billion USD by 2024 on February 12, 2019 at 11:25 pm
Rise in awareness regarding early disease diagnosis and prevention will boost the demand for point of care molecular diagnostics. Applications such as drug regimen selection, patient stratification, t... […]
- An affirmation of alternatives on February 11, 2019 at 2:40 am
Antibodies form the basis of many of these assays, from pregnancy tests to the identification of infectious disease, and the diagnosis and monitoring of cancer patients ... an increased interest in si... […]
- DrFirst Launches CURES 2.0 Integration Through MEDITECH EHR on February 7, 2019 at 9:48 am
This newest initiative in DrFirst’s long-time fight to end the opioid epidemic is point-of-care technology that ... and California’s prescription drug monitoring program (PDMP). […]
via Google News and Bing News